Epidemiology of sarcopenia in patients receiving programmed hemodialysis treatment
https://doi.org/10.24884/1609-2201-2024-103-3-25-33
Abstract
Background. Sarcopenia is a clinically significant complication of long-term therapy with chronic hemodialysis and is an independent prognostic factor of morbidity and mortality. This explains the need for its timely and accurate diagnosis.
The aim of the study was to study the epidemiological aspects of sarcopenia in patients receiving treatment with programmed hemodialysis.
Methods and material. 317 patients treated with programmed bicarbonate hemodialysis for 8.2 ± 5.1 years were examined, among them 171 women and 146 men, the average age was 57.1±11.3 years. The assessment of the presence of sarcopenia was performed using a technique recommended by the European Working Group on Sarcopenia in Older People.
Results. The prevalence of presarcopenia was 0.7% (2 patients) and sarcopenia 29.6% (93 patients). The presence of skeletal muscle mass deficiency according to the muscle mass index (MMI) was 30.3% (95 patients), a decrease in muscle strength according to dynamometry was noted in 153 patients (48.7%), low skeletal muscle performance according to the results of the 6-minute walking test was determined in 134 patients (42.8%).
Conclusion. The prevalence of sarcopenia in hemodialysis patients is 29.6%. The duration of hemodialysis therapy and the age of the patient are independent risk factors for the development of sarcopenia.
About the Authors
A. Sh. Rumyantsev
Saint Petersburg State University
Russian Federation
Russian Federation
Alexander Sh. Rumyantsev, Dr. of Sci. (Med.), Professor of the Department of Faculty Therapy of the Medical Faculty
7/9 Universitetskaya Emb., Saint Petersburg, 199034
Ju. V. Lavrishcheva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Yuliya V. Lavrishcheva, Cand of Sci. (Med.), Associate Professor of the Department of Faculty Therapy with a Clinic
Saint Petersburg
A. A. Jakovenko
Pavlov University
Russian Federation
Russian Federation
Alexander A. Jakovenko, Cand of Sci. (Med.), Associate Professor of the Department of nephrology and dialysis
Saint Petersburg
A. G. Kucher
Pavlov University
Russian Federation
Russian Federation
Anatoliy G. Kucher, Dr. of Sci. (Med.), Professor, Professor of the Department of Propaedeutics of Internal Diseases with clinic named after acad. M. D. Tushinksy
Saint Petersburg
References
1. Kittiskulnam P., Chertow G. M., Carrero J. J. et al. Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int. 2017;92(1):238– 247. https://doi.org/10.1016/j.kint.2017.01.024.
2. Giglio J., Kamimura M. A., Lamarca F. et al. Association of sarcopenia with nutritional parameters, quality of life, hospitalization, and mortality rates of elderly patients on hemodialysis. J Ren Nutr. 2018;28(3):197–207. https://doi.org/10.1053/j.jrn.2017.12.003.
3. Bataille S., Serveaux M., Carreno E. et al. The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients. Clin Nutr. 2017;36(6):1654–1660. https://doi.org/10.1016/j.clnu.2016.10.016.
4. Messina C., Maffi G., Vitale J. A. et al. Diagnostic imaging of osteoporosis and sarcopenia: a narrative review. Quant Imaging Med Surg. 2018;8(1):86–99. https://doi.org/10.21037/qims.2018.01.01.
5. Battaglia Y., Galeano D., Cojocaru E. et al. Muscle-wasting in end stage renal disease in dialysis treatment: a review. G Ital Nefrol. 2016;33(2):gin/33.2.7.
6. Cruz-Jentoft A. J., Baeyens J. P., Bauer J. M. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–423. https://doi.org/10.1093/ageing/afq034.
7. Arias-Guillén M., Perez E., Herrera P. et al. Bioimpedance Spectroscopy as a Practical Tool for the Early Detection and Prevention of Protein-Energy Wasting in Hemodialysis Patients. J Ren Nutr. 2018;21:S1051–2276(18)30057-8. https://doi.org/10.1053/j.jrn.2018.02.004.
8. Guglielmi G., Ponti F., Agostini M. et al. The role of DXA in sarcopenia. Aging Clin Exp Res. 2016;28(6):1047–1060. https://doi.org/10.1007/s40520-016-0589-3.
9. Popovic V., Zerahn B., Heaf J. G. Comparison of dual energy X-ray absorptiometry and bioimpedance in assessing body composition and nutrition in peritoneal dialysis patients. J Ren Nutr. 2017;27(5):355–363. https://doi.org/10.1053/j.jrn.2017.03.003.
10. Kittiskulnam P., Carrero J. J., Chertow G. M. et al. Sarcopenia among patients receiving hemodialysis: weighing the evidence. J Cachexia Sarcopenia Muscle. 2017;8(1):57–68. https://doi.org/10.1002/jcsm.12130.
11. Dehesa-López E., Correa-Rotter R., Olvera-Castillo D. et al. Transcultural adaptation and validation of the Mexican version of the kidney disease questionnaire KDQOL-SF36 version 1.3. Qual Life Res. 2017;26(1):193–198. https://doi.org/10.1007/s11136-016-1365-8.
12. Cao L., Morley J. E. Sarcopenia is recognized as an independent condition by an international classification of disease, tenth revision, clinical modification (ICD-10-CM) code. J Am Med Dir Assoc. 2016;17(8):675–677. https://doi.org/10.1016/j.jamda.2016.06.001.
13. European best practice guidelines. Guideline on Nutrition. Nephrol Dial Transplant. 2007;22(Suppl 2):45–87.
14. Polyzos S. A., Margioris A. N. Sarcopenic obesity. Hormones (Athens). 2018;17(3):321–331. https://doi.org/10.1007/s42000018-0049-x.
Review
For citations:
Rumyantsev A.Sh., Lavrishcheva J.V., Jakovenko A.A., Kucher A.G. Epidemiology of sarcopenia in patients receiving programmed hemodialysis treatment. New St. Petersburg Medical Records. 2024;(3):25-33. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-3-25-33
Views:
58
Email this article 